Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by StockHawk1on Mar 02, 2023 5:27pm

100 Views

Post# 35316216

AGN appoints TBI expert for TBI-DMT study

Algernon Pharmaceuticals Inc. (AGN.c AGNPF) has appointed Global TBI Expert, Dr. David L. Brody as a consultant for its TBI-DMT clinical research program.

Brody was a Professor of Neurology and director of the NFL Neurological player care program at Washington University.

Good to see that AGN's study of using DMT to treat TBI will be backed by such expertise.

https://finance.yahoo.com/news/algernon-neuroscience-appoints-global-tbi-130000428.html

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages